Elucid Announces First Patient Enrollment in AI-PREDICT, a Landmark International Study to Define Lesion-Level Cardiovascular Risk
Multicenter Retrospective Study Will Analyze Lesions Using AI-Powered CCTA Analysis, Advancing Elucid’s CCTA 3.0 Vision for Personalized CAD Treatment
Elucid, an innovator in AI-powered coronary CT angiography (CCTA) analysis, today announced first patient enrollment in AI-PREDICT, a retrospective, international, multicenter study designed to establish a new lesion-centric paradigm for cardiovascular risk stratification. Enrollment is underway at three of more than 20 planned sites across the U.S., Europe, and Asia: Emory University, the Medical University of South Carolina, and Centro Cardiologico Monzino, Milan, led by site principal investigators Carlo N. De Cecco, MD, PhD, Akos Varga-Szemes, MD, PhD, MBA, and Gianluca Pontone, MD, PhD, respectively.
AI-PREDICT will enroll approximately 1,000 subjects, including both patients who experienced a myocardial infarction (MI) within 36 months of a baseline CCTA and clinically matched, event-free controls, generating a dataset of individual coronary lesions. All scans will be analyzed by a central core lab, blinded to outcomes, using Elucid’s Plaque-IQ™ and FFR-CT1 software to measure key morphological, anatomical and physiological features.
